BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Huang R, Shi XL, Wang YF, Yang F, Wang TT, Peng CX. Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: A case report. World J Clin Cases 2019; 7(22): 3881-3886 [PMID: 31799318 DOI: 10.12998/wjcc.v7.i22.3881]
URL: https://www.wjgnet.com/2307-8960/full/v7/i22/3881.htm
Number Citing Articles
1
Suiting Ye, Song Zheng. Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma PeritoneiAmerican Journal of Clinical Oncology 2022; 45(5): 223 doi: 10.1097/COC.0000000000000911
2
D.V. Sidorov, N.A. Grishin, M.V. Lozhkin, N.A. Rubtsova, N.N. Volchenko, A.A. Troitsky, I.V. Stepanyuk, S.A. Bykasov, A.O. Peshkov, R.I. Moshurov. Reoperations in patients with pseudomyxoma peritoneiOnkologiya. Zhurnal imeni P.A.Gertsena 2021; 10(6): 14 doi: 10.17116/onkolog20211006114
3
Sinziana Ionescu, Marian Marincas, Octavia Luciana Madge, Irinel Gabriel Dicu-Andreescu, Elena Chitoran, Vlad Rotaru, Ciprian Cirimbei, Mirela Gherghe, Adina Ene, Robert Rosca, Madalina Radu, Laurentiu Simion. Ovarian Causes of Pseudomyxoma Peritonei (PMP)—A Literature ReviewCancers 2024; 16(8): 1446 doi: 10.3390/cancers16081446